Stryker Corporation

Stryker Corporation

SYK
Stryker CorporationUS flagNew York Stock Exchange
269.75
USD
-3.65
- -
103.41BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
23.83
25.56
26.41
30.27
33.27
36.36
39.8
38.22
45.38
48.78
54
59.3
65.71
67.49
Basic EPS, GAAP
2.66
1.36
3.82
4.4
2.73
9.5
5.57
4.26
5.29
6.23
8.34
7.86
8.49
9.74
Free Cash Flow per Basic Share
4.47
4.09
1.89
3.81
2.57
5.45
4.12
7.43
7.26
5.38
8.26
9.15
11.21
12.28
Dividend per Share
1.06
1.22
1.38
1.52
1.7
1.88
2.08
2.3
2.52
2.78
3
3.2
3.36
3.44
Book Value per Share
23.93
22.74
22.82
25.47
26.62
31.33
34.2
34.79
39.41
43.88
48.92
54.1
58.61
62.54
Tangible Book Value per Share
8.5
6.33
6.92
-0.84
-1.81
-2.66
-1.31
-13.95
-7.63
-8.32
-3.27
1.01
-6.67
-3.49
Basic Weighted Avg Shares
379
378
377
374
374
374
374
376
377
378
380
381
382
383
Sales/Revenue/Turnover
9,021
9,675
9,946
11,325
12,444
13,601
14,884
14,351
17,108
18,449
20,498
22,595
25,116
25,837
Operating Margin (%)
20.82
20.74
21.69
20.6
19.85
18.82
19.52
15.61
15.71
16.86
19.14
20.65
20.14
21.73
Depreciation Expense
307
378
397
546
642
723
778
812
990
998
1,028
1,050
1,193
1,221
Net Income, GAAP
1,006
515
1,439
1,647
1,020
3,553
2,083
1,599
1,994
2,358
3,165
2,993
3,246
3,729
Effective Tax Rate (%)
17
55.6
17.06
14.26
50.56
- -
18.7
18.17
12.58
12.11
13.83
14.29
28.09
27.56
Profit Margin (%)
11.15
5.32
14.47
14.54
8.2
26.12
13.99
11.14
11.66
12.78
15.44
13.25
12.92
14.43
Working Capital
5,678
4,223
4,441
4,713
4,508
4,926
6,658
4,666
5,468
3,972
4,597
7,231
6,961
7,734
LT Debt
2,739
3,246
3,230
6,686
6,590
8,486
10,231
13,230
12,472
11,857
10,901
12,188
14,859
14,192
Total Equity
9,047
8,595
8,511
9,550
9,980
11,730
12,807
13,084
14,877
16,616
18,593
20,634
22,420
23,988
Return on Invested Capital (%)
14.02
7.21
14.07
13.78
7.24
- -
10.34
7.17
8.61
9.56
10.98
12.05
9.96
10.62
Return on Capital (%)
9.08
4.22
11.48
11.37
6.06
- -
9.16
6.27
7.33
8.27
11.36
10.16
10.16
10.27
Return on Common Equity (%)
11.4
5.84
16.82
18.24
10.45
32.75
16.98
12.35
14.26
14.97
17.98
15.26
15.08
16.51

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,000
499
750
LT Borrowings
14,859
14,224
14,192
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
382
383
384
Market Capitalization
134,437
125,969
120,764

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
14,755
13,338
14,418
Cash, Cash Equivalents & STI
4,100
2,965
3,476
Accounts Receivable, Net
4,039
3,571
3,743
Inventories
5,310
5,419
5,521
Total Current Liabilities
7,794
6,315
6,684
Payables & Accruals
5,199
4,931
4,829
ST Debt
1,000
499
750
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.25%
11.39%
8.66%
Free Cash Flow
29.71%
12.11%
22.83%
Net Income, GAAP
24.03%
16.04%
8.45%
Sales/Revenue/Turnover
9.84%
11.91%
11.16%
Total Cash Common Dividend
9.46%
8.29%
5.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,243
5,422
5,494
6,436
22,595
2025
5,866
6,022
6,057
7,171
25,116
2026
6,020
6,589
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.07
2.17
2.19
1.43
7.86
2025
1.71
2.31
2.25
2.22
8.49
2026
1.95
3.33
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.8
0.8
0.8
0.8
3.2
2025
0.84
0.84
0.84
0.84
3.36
2026
0.88
0.88
- -
- -
- -

Company Description

CEO
Kevin A. Lobo
Full Time Employees
56,000
Sector
Healthcare
Industry
Medical - Devices
Address
1941 Stryker Way Portage MI United States of America 49002
IPO Date
Mar 17, 1980
Business
Stryker Corporation (NYSE: SYK) develops, manufactures, and markets medical technologies, including orthopedic implants and instruments; surgical equipment and navigation systems; endoscopic and communications products; and patient handling and emergency medical equipment. The company offers its Mako robotic-arm assisted surgery platform for orthopedic procedures; Triathlon and Trident hip and knee systems; Gamma3 and T2 intramedullary nailing systems; and Ceros and Variax distal fixation systems, among other specialized devices for joint reconstruction, trauma and extremities, and spine care. Stryker provides interventional devices, including embolic products and guidewires, along with neurotechnology and spine products such as Vizor vision systems and SurgiCount safety sponges; it also delivers solutions for operating room integration and capital equipment. Founded in 1941 and headquartered in Kalamazoo, Michigan, the company operates globally across the Americas, Europe, Asia-Pacific, and other regions, serving hospitals, ambulatory surgery centers, and healthcare providers in the medtech industry. In recent developments, Stryker completed the acquisition of Artelon AB in September 2024, enhancing its sports medicine portfolio with advanced biomaterials for soft tissue regeneration. The company also acquired Wright Medical Group N.V. in 2022, bolstering its extremity reconstruction offerings, and continues to expand through strategic investments, including a new manufacturing facility in Ireland to support European growth. Additionally, Stryker launched the next-generation Mako Total Knee 2.0 application and advanced its Blue Seal bipolar sealer technology, reflecting ongoing innovation in robotics and surgical efficiency amid robust demand in orthopedics and neurotechnology segments.

Company News

  • Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?

  • Can Stryker Vehicle Demand Support General Dynamics' Growth?

  • Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

  • Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK

  • SYK Investors: Contact Block & Leviton Regarding Its Ongoing Investigation of Stryker Corporation

  • Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX

  • Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

  • GEHC or SYK: Which Is the Better Value Stock Right Now?

  • Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™

  • Stryker: Operational Issues Have Created An Opportunity

  • Stryker ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

  • Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Securities Fraud Investigation Into Stryker Corporation (SYK) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • SYK ALERT: Stryker Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm

  • Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  • Stryker Corporation $SYK Shares Purchased by California State Teachers Retirement System

  • Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference